Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.52 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329523 | 0.86 | CNR1 (0.45) | MTNR1AMTNR1BNOTUMMETRIPK1 | |
| SCHEMBL3568253 | 0.84 | P2RX7 (0.53) | P2RX7MAOBEPHX2METNR1H4 | |
| SCHEMBL4489127 | 0.83 | P2RX7 (0.54) | P2RX7BDKRB1MTNR1B | |
| SCHEMBL30259905 | 0.83 | P2RX7 (0.56) | P2RX7MAOBPDE10AMEN1KMT2A | |
| SCHEMBL2831744 | 0.83 | P2RX7 (0.56) | P2RX7 | |
| SCHEMBL23482150 | 0.83 | P2RX7 (0.56) | P2RX7MAOBPDE10AMEN1KMT2A | |
| SCHEMBL18887627 | 0.83 | P2RX7 (0.50) | P2RX7BDKRB1MAOB | |
| SCHEMBL5317199 | 0.82 | P2RX7 (0.49) | P2RX7MAOBEPHX2METPDE10A | |
| SCHEMBL626266 | 0.82 | P2RX7 (0.49) | P2RX7MAOBEPHX2NOTUMMET | |
| SCHEMBL7258138 | 0.81 | HDAC1 (0.43) | P2RX7BDKRB1MTNR1AMTNR1BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| WO-2023125825-A1 | ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2021-09-14 | — | — | US | disclosed |
| US-11066411-B2 | — | — | 2021-07-20 | — | — | US | disclosed |
| EP-3265445-B1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2020-04-30 | — | — | US | disclosed |
| WO-2020039060-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-02-27 | — | — | WO | disclosed |
| EP-3613738-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | Lead Discovery Center GmbH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-03-01 | — | — | US | disclosed |
| US-9656962-B2 | Ring-contracted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160340316-A1 | RING-CONTRACTED MORPHINANS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2016-11-24 | — | — | US | disclosed |
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016144702-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-9346807-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058103-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | P2RX7 2340/4885BDKRB1 2332/4885MAOB 3408/4885 |
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | ADORA2A, ADORA1, ADORA3 | P2RX7 32/4885BDKRB1 49/4885MAOB 174/4885 |
| US-11066411-B2 | — | ADORA2A, ADORA1, ADORA2B | P2RX7 110/4885BDKRB1 39/4885MAOB 288/4885 |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA1, ADORA3 | P2RX7 32/4885BDKRB1 49/4885MAOB 174/4885 |
| US-20160340316-A1 | RING-CONTRACTED MORPHINANS AND THE USE THEREOF | OPRM1, OPRL1, OPRK1 | P2RX7 471/4885BDKRB1 126/4885MAOB 374/4885 |
| US-10766860-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | P2RX7 2605/4885BDKRB1 2364/4885MAOB 62/4885 |
| US-20180057458-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | P2RX7 2605/4885BDKRB1 2364/4885MAOB 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.